Because next-generation sequencing analysis of the tumor had revealed a NTRK1-mutation and the pan-TRK inhibitor entrectinib was effective in HCC-NED organoids, a therapy attempt with entrectinib was suggested for second line. This evidence concerns the gene NTRK1 and neoplasm.